We have developed a new BMT method, intra-BM-BMT (IBM-BMT), in which donor BM cells (BMCs) are directly injected into the recipient's BM, resulting in a rapid recovery of donor hematopoiesis and a reduction in the severity of GVHD. In the present experiment, we attempted to retain the number of injected BMCs using magnetic beads and a magnet. The BMCs of donor mice were conjugated with magnetic beads, and these cells were then injected into the BM of recipient mice with a magnet (magnet-IBM group) and compared with conventional IBM-BMT without a magnet (IBM group). A significantly higher number of transplanted cells were detected in the injected BM in the magnet-IBM group. We next carried out day-12 colony-forming units of spleen (CFU-S) assays to examine the early stage of hematopoiesis of the injected host hematopoietic stem cells after IBM-BMT. The spleens of mice in the magnet-IBM group showed considerably higher CFU-S counts than those in the IBM group. Excellent reconstitution of donor hematopoietic cells in the magnet-IBM group was observed 1 month after IBM-BMT. These results suggest that the IBM-BMT using the combination of magnetic beads and a magnet is superior to the conventional IBM-BMT.
Introduction
BMT is an effective therapy for congenital immunodeficiency diseases and malignant tumors. However, because of the inherent risks, which include GVHD, graft rejection, graft failure, veno-occlusive disease and infections, it is not easy to carry out. [1] [2] [3] [4] [5] With graft failure and infections, donor hematopoiesis is suppressed. To reduce the risk of graft failure and infections, it is important to ensure the rapid recovery of donor hematopoiesis.
Intra-BM-BMT (IBM-BMT) is a newly developed method for BMT. The merits of IBM-BMT include a reduction in the severity of GVHD and a more rapid recovery of donor hematopoiesis. [6] [7] [8] [9] In the IBM-BMT method, donor BM cells (BMCs) are directly injected into the recipient's BM, and a much greater number of donor hematopoietic stem cells (HSCs) and MSCs can therefore be inoculated into the recipient's BM than in the conventional i.v. BMT, which thus results in a rapid reconstitution of donor hematopoietic cells and permits a reduction in the radiation doses used as a pretreatment for the BMT. In addition, we have shown that IBM-BMT can be used for organ transplantation, with the engrafted organs surviving for a long period without the use of immunosuppressants. 7, 8, [10] [11] [12] We have also reported that, even when using the IBM-BMT method, some of the injected BMCs enter into the peripheral circulation. 13 To suppress this leakage into the peripheral circulation, we used collagen gel, which helps retain the donor BMCs in the recipient's BM, resulting in the rapid recovery of donor hematopoiesis. 13 However, collagen gel is prepared from animal protein, and could therefore induce an allergic reaction.
The combination of magnetic beads and a permanent magnet is usually used for negative or positive selection of suspended cells.
14 Clinically, cells separated by the combination of magnetic beads and a magnet are used for BMT. 15 In this experiment, we used magnetic beads (Dynabeads, Dynal Biotech ASA, Oslo, Norway) and a magnet to help retain the donor's hematopoietic cells in the recipient's BM, resulting in a rapid recovery of donor hematopoiesis.
Materials and methods
Mice C57BL/6 (B6) mice, BALB/c mice, ICR mice and B6 mice carrying enhanced green fluorescent protein (eGFP mice) were purchased from Japan SLC, Inc. (Hamamatsu, Japan). 16 These mice were used at 8-9 weeks of age. All mice were maintained in a pathogen-free environment, and all manipulations were performed in a laminar flow hood. The university's committee for animal research approved all experiments.
Reagents
The Abs used in this study were as follows: phycoerythrin (PE)-labeled anti-mouse CD3 Ab, PE-labeled anti-mouse B220 Ab, PE-labeled anti-mouse Gr-1 Ab, PE-labeled anti-H-2 K d Ab, peridinin chlorophyll protein (PerCP)-Cy5.5-labeled anti-mouse CD45 Ab, biotin-labeled anti-CD45 Ab, biotin-labeled anti-Sca-1 Ab, FITC-labeled anti-H-2K b Ab and allophycocyanin-labeled anti-c-kit Ab (BD Pharmingen, San Diego, CA, USA). Streptavidin-conjugated Dynabeads were from Dynal Biotech ASA. Viaprob (BD Pharmingen) was used to eliminate dead cells.
Whole-body irradiation of recipient mice Gamma-irradiation was delivered by a Gammacell 40 Exactor (MDS Nordion, Kanata, ON, Canada) with two 137 Cs sources. Recipient mice were irradiated with 7, 8, 9 or 10 Gy the day before BMT.
Treatment of donor BM cells BM cells were flushed out from the femurs and tibias of donor mice with PBS. After gentle dissociation, the BMC suspension was filtered through a 70-mm nylon mesh (BD Falcon, Franklin Lakes, NJ, USA), and the BMCs were counted. The BMC suspension was centrifuged and the supernatant was discarded. The BMCs were then incubated with biotin-labeled anti-CD45 Ab and biotin-labeled antiSca-1 Ab as first Abs, followed by streptavidin-labeled Dynabeads (Figures 1a-c) .
The experimental mice were divided into two groups: (i) the IBM group, in which BMCs conjugated with magnetic beads were injected into the tibia, and (ii) a magnet-IBM group, in which BMCs conjugated with magnetic beads were injected into the tibia and fixed with a magnet. In this experiment we used a ring-type magnet (Magfine, Sendai, Japan). Finally, BMCs were adjusted to 10 7 , 10 8 or 10 9 cells per milliliter.
BMT
One day after irradiation, the BMCs of B6 mice, eGFP tg mice or BALB/c mice were transplanted into recipient B6 mice directly into the bone cavity by way of IBM-BMT, as described previously. 6 Briefly, the mice were anesthetized and the area from the inguinal region to the knee joint was shaved. The tibia was gently drilled with a 26-G needle through the patellar tendon into the BM cavity. BMCs conjugated with magnetic beads were aspirated into a microsyringe (50 ml; Ito, Fuji, Shizuoka, Japan). The BMCs were then injected into the BM cavity using the microsyringe. In this procedure, a ring magnet was used (as shown in Figures 1d and e) before the injection only in the magnet-IBM group. The ring magnet was then kept in that position for about 30 min after the injection (Figure 1f ).
Colony-forming units of spleen (CFU-S) assay
For the CFU-S assay, the BMCs of B6 mice (10 5 cells in 10 ml per mouse) were transplanted into the BM of B6 mice 1 day after 9 Gy irradiation. The recipient B6 mice were killed on day 12 after BMT, and their spleens were removed and fixed in Bouin's solution. Visible surface colonies were counted 1 day after fixing. The following groups were prepared for day 12 CFU-S assays: (i) a control group, in which only PBS was injected via IBM-BMT, (ii) an IBM group, in which BMCs were injected by IBM-BMT without the use of a magnet, and (iii) a magnet-IBM group, in which BMCs were injected by IBM-BMT with the use of a magnet.
Analysis of donor cells in recipient BM and peripheral blood (PB)
To detect donor-derived PB nuclear cells, the BMCs of eGFP tg mice (10 6 cells in 10 ml per mouse) were transplanted into the BM of B6 mice the day after 7 or 8-Gy irradiation. An IBM group and a magnet-IBM group were prepared. The PB of the recipient mice was examined 1 month, 2 months and 100 days after the BMT. The PB of each mouse was divided into three lots, and samples from each mouse were incubated with PE-conjugated CD3 and PerCP-Cy5.5-conjugated CD45, PE-conjugated B220 and PerCP-Cy5.5-conjugated CD45, or PE-conjugated Gr1 and PerCP-Cy5.5-conjugated CD45. The stained cells were analyzed using a FACSCalibur instrument equipped with CellQuest software. The cells were first gated by CD45 þ cells. The eGFP þ /CD45 þ cells were considered to be donor-derived WBCs. The percentages of donor T lymphocytes, donor B lymphocytes and granulocytes were estimated as eGFP 
Statistical analysis
The results are represented as means±s.d. Student's t-test was used to determine statistical significance. A P-value o0.05 was considered to be significant.
Results
The magnet-IBM group shows significantly higher day-12 CFU-S counts after IBM-BMT than the IBM group We carried out day-12 CFU-S assays to examine the activity of HSCs/immature hematopoietic progenitor cells (IHPCs) after IBM-BMT using the magnetic beads and the magnet (Figure 2 ). First, we analyzed the day-12 CFU-S using B6 mice (B6 into B6 mice). In the magnet-IBM group 13.8 ± 6.8 colonies/spleen were observed on day 12, whereas in the IBM group 8.0±5.9 colonies/spleen were observed (Po0.05) (Figure 2a ). The spleens in the . Next, the cells were incubated with streptavidincoupled magnetic beads (Dynabeads), so that the magnetic beads became attached to the BMCs (c). In this figure, we show hematopoietic stem cells expressing Sca-1. The magnetic beads can attach to the hematopoietic stem cells through Sca-1 and CD45. The magnetic beads can also attach to other types of BMCs not expressing Sca-1 through CD45. The BMCs conjugated with magnetic beads were injected into the BM of the tibia fixed with the magnet (d and e). After IBM-BMT, the magnet was fixed to the tibia (f).
magnet-IBM group were larger than those in the IBM group (Figure 2b) .
To confirm this phenomenon, we carried out day-12 CFU-S assays using ICR mice (ICR into ICR mice), another mouse strain. Even in ICR mice, more colonies were observed in the spleens of the magnet-IBM group than in those of the IBM group (Figure 2c) . These results suggest that hematopoiesis of donor BMCs can be accelerated in the magnet-IBM group.
Reduced radiation doses as pretreatment for BMT in the magnet-IBM group Next, we examined whether radiation doses could be reduced when IBM-BMT was carried out with the combination of magnetic beads and the magnet (Figure 3a) . First, we irradiated recipient B6 mice at 8 Gy and reconstituted them with eGFP mouse BMCs by IBM-BMT. In this experiment, both the IBM groups and the magnet-IBM showed good reconstitution of donor hematopoietic cells 1 month after BMT. There was no significant difference between the two groups: the mean and s.d. of % donor cells in the IBM group and the magnet-IBM group were 67.02 ± 11.27% and 70.99 ± 11.07%, respectively. We therefore reduced the radiation dose from 8 to 7 Gy. With 7 Gy radiation, significantly higher percentages of reconstitution with donor cells were observed in the magnet-IBM group than in the IBM group 1 month after BMT: the means±s.d. were 71.96±5.17% in the magnet-IBM group and 50.7 ± 12.62% in the IBM group. These results suggest that the IBM injection using the combination of magnetic beads and magnet is effective in reducing irradiation doses as a pretreatment.
Next, we examined whether cells of various lineages could differentiate in the magnet-IBM group. As shown in Figures 3b-d , donor BMCs had differentiated into multilineage hematopoietic cells in both the IBM and the magnet-IBM groups 1 month after IBM-BMT. There were no significant differences in % donor cells in CD3 þ cells or B220 þ cells (Figures 3b and c) , although the percentages of donor cells in Gr-1 þ cells had increased significantly in the magnet-IBM group (Figure 3c ). There were no significant differences in the percentages of donor hematopoietic cells in the PB between the IBM group and magnet-IBM group 2 months or 100 days after IBM-BMT (74.61±3.47% in the IBM group and 72.52 ± 10.53% in the magnet-IBM group 2 months after IBM-BMT, and 76.67 ± 4.29% in the IBM group and 72.24±14.35% in the magnet-IBM group 100 days after IBM-BMT). Therefore, donor hematopoiesis in the IBM group had caught up with that in the magnet-IBM group by 2 months after the IBM-BMT. These results suggest that the combination of the magnetic beads and the magnet accelerates the recovery of donor hematopoiesis after IBM-BMT.
The combination of magnetic beads and magnet helps retain more BMCs than conventional IBM-BMT To clarify the mechanisms of acceleration of donor hematopoiesis as a result of using the combination of magnetic beads and magnet, we examined whether this combination could help retain more injected cells in the injected BM than the conventional IBM-BMT. We carried out IBM-BMT using magnetic bead-coated BMCs with or without the magnet from BALB/c to B6 mice, and then estimated the percentage of BMCs from BALB/c mice in the BMC-injected tibia of B6 mice an hour later (Figure 4 ). More donor BMCs were detected in the BM of the magnet-IBM group than in that of the IBM group, suggesting that the combination of magnetic beads and magnet helped retain more injected donor BMCs in the recipient's BM than the conventional IBM method.
Discussion
This experiment showed that IBM-BMT using the magnetic beads and magnet helped retain the BMCs in the recipient's BM, thereby accelerating donor hematopoiesis Figure 2 The combination of magnetic beads and magnet can accelerate donor hematopoiesis. The day-12 colony-forming units of spleen (CFU-S) assay was carried out using B6 mice (a and b) and ICR mice (c). The mice were irradiated at 9 Gy, and the day after the irradiation, the mice were injected with syngeneic BM cells (BMCs) or PBS, as described in Materials and methods. At 12 days after BMT, the mice were killed to assay the day-12 CFU-S. n ¼ 6 (control; mice injected with only PBS), 6 (IBM) and 9 (magnet-IBM). *Po0.05.
and allowing a reduction in the radiation doses used as a pretreatment for BMT. In 2001, we first reported that IBM-BMT promoted the rapid recovery of donor hematopoiesis in BMT, 6 and that IBM-BMT could be used to treat intractable autoimmune diseases in MRL/Mp-lpr/lpr mice, which are resistant to conventional i.v. BMT therapy. 6 We have also shown the advantages of IBM-BMT not only in the treatment of hematopoietic diseases but also in organ transplantations and treatments for solid malignant tumors. [17] [18] [19] [20] [21] In these experiments, we showed that IBM-BMT induced rapid recovery of donor hematopoietic cells, easily induced tolerance in the recipients, reduced the severity of GVHD and permitted a reduction in the radiation doses used as a pretreatment for BMT. The benefits of IBM-BMT could be due to the direct injection of donor BMCs into the recipient's BM, resulting in the retention of a much greater number of donor BMCs in the recipient's BM than with i.v. BMT, thereby accelerating donor hematopoiesis. [6] [7] [8] [9] In IBM-BMT, the injected HSCs/IHPCs expand and differentiate in the injected BM, and the mature hematopoietic cells and some HSCs/IHPCs then enter into the PB. 8, 13 The HSCs/IHPCs move to and settle in the BM of other bones and the spleen. 8, 13 In the spleen, the HSCs/IHPCs could form CFU-S. Our previous experiment showed that i.v. BMT results in higher CFU-S counts than IBM-BMT at 5 days after BMT, but IBM-BMT results in higher CFU-S counts than i.v. BMT at 9 and 12 days after BMT. 13 These results suggest that IBM-BMT is eventually more effective in accelerating donor hematopoiesis than i.v. BMT.
We have found that some of the injected BMCs get into the blood vessels, and thereby into peripheral circulation, even with IBM-BMT. 13 In this paper, we used the combination of magnetic beads and magnet to retain the donor BMCs in the recipient's BM. The combination of Dynabeads and a magnet is usually used for negative selection or positive selection of suspended cells. The target cells, which become attached to the Dynabeads, are attracted to the magnet. We positioned the ring-type magnet around the injected bone (tibia) so that the injected donor BMCs could be drawn to the edge of the BM, which means that they were located adjacent to the bone (Figure 1d ). It has been reported that niche cells can maintain HSCs, and that they can regulate the quiescent Magnet-IBM * Figure 4 Intra-BM-BMT (IBM-BMT) using the combination of magnetic beads and magnet helps retain more donor BM cells (BMCs) in the injected BM than the conventional IBM-BMT. B6 mice were irradiated at 10 Gy. The day after the irradiation, the B6 mice were transplanted with BMCs from BALB/c mice using only PBS injection (control) or the conventional IBM-BMT (IBM), or the combination of magnetic beads and magnet (magnet-IBM). At 1 h after the IBM-BMT, the mice were killed and the percentages of donor BMCs were analyzed using a flow cytometer, as described in Materials and methods. n ¼ 5 (control; mice injected with only PBS), 6 (IBM), and 5 (magnet-IBM). *Po0.05.
and proliferative stages of HSCs. 22, 23 It has also been reported that the niche cells and the HSCs exist at the margins of the BM. 22, 23 It was therefore plausible to draw the HSCs to the margins of the BM using the combination of magnetic beads and magnet. As it has been reported that both HSCs/IHPCs and MSCs express Sca-1 Ag, the magnetic beads should be able to attach not only to HSCs/ IHPCs but also to MSCs, thereby helping the interaction between HSCs/IHPCs and MSCs. 24, 25 This could be favorable for the regulation of hematopoiesis.
We have shown that the combination of magnetic beads and magnet not only helps retain the intra-BM-injected BMCs in the BM (Figure 4 ) but can also accelerate the hematopoiesis of the donor BMCs (Figures 2 and 3) . We assumed that this acceleration of hematopoiesis would be attributable both to the retention of large numbers of donor HSCs in the BM as well as to the interaction between the niche cells and the HSCs. Therefore, we examined whether using the magnet for a longer duration might be more effective in helping retain the injected cells in the recipient BM than using it for 30 min, thereby augmenting the effect of the magnet-IBM. When we used the magnet for 90 min, we observed higher CFU-S counts and greater numbers of donor hematopoietic cells in the PB than when using it for 30 min (data not shown). These results suggest that the grater the number of donor BMCs retained in the recipient BM, the more rapidly donor hematopoiesis occurs as we predicted. 8, 13 It should be noted that mice are too small to be able to clarify the mechanisms underlying the accelerated hematopoiesis in our method. Experiments using larger animals are needed in order to be able to elucidate the mechanisms. In our experiment, the proliferation of myeloid lineage cells was accelerated but the proliferation of lymphoid cells (T cells and B cells) was not accelerated at 1 month after IBM-BMT (Figure 3) , and the percentage of donor cells in the IBM group had caught up with that in the magnet-IBM group by 2 months after IBM-BMT. The reconstitution rate of the donor hematopoietic cells in the PB 3 months after IBM-BMT was similar to that 2 months after IBM-BMT. These results suggest that the combination of magnetic beads and magnet can accelerate donor hematopoiesis but cannot change the final reconstitution rate of donor cells.
Iron overload could induce hemosiderosis or hemocromatosis, which would damage various organs. The magnetic beads we used were made from iron and there was a risk that the magnetic beads could induce iron overload. We killed the mice 9 months after magnet-BMT and histologically examined the liver, pancreas, spleen, kidneys, heart and lungs. We did not detect any deposition of iron in any of these organs, nor did we detect any changes in the organs in comparison with age-matched normal mice. However, before this method is applied to humans, the absolute safety of the materials must be confirmed.
By this experiment, we have demonstrated that the combination of magnetic beads and magnet can accelerate donor hematopoiesis after IBM-BMT by helping retain larger numbers of donor BMCs in the BM of the recipients.
